Icosabutate (NST-4016) is an orally active derivative of eicosapentaenoic acid that inhibits hepatic inflammation and fibrosis in NASH, improves cardiovascular risk profiles in statin-treated patients with residual hypertriglyceridemia, lowers triglycerides, and may be useful in studies of liver fibrosis and atherosclerosis.

在 6-8 周龄的 ob/ob 雄性小鼠中，Icosabutate（每日通过饮食给予 135 mg/kg;连续给药 5 周）能够改善葡萄糖代谢和胰岛素抵抗[1]。